Yeah, I think this was an important viewpoint which I wrote together with some prominent psychiatrists in Europe on a very important topic which you know has to be taken into account by both us neurologist by psychiatrists and then this is the issue of tardive dyskinesia which is a very common result of chronic antipsychotic treatment, sometimes not well recognized by specialists but possibly very disabling for patients...
Yeah, I think this was an important viewpoint which I wrote together with some prominent psychiatrists in Europe on a very important topic which you know has to be taken into account by both us neurologist by psychiatrists and then this is the issue of tardive dyskinesia which is a very common result of chronic antipsychotic treatment, sometimes not well recognized by specialists but possibly very disabling for patients. So it’s important to recognize it. It’s important to treat it when possible and at least probably 20% of people taking chronic antipsychotic therapy sooner or later will develop tardive syndromes in particular tardive dyskinesia which is the most classical one, mainly involving the oral-buccal-lingual region. And because of that very disabling also for cosmetic reasons. And the advancement we have at the moment are that there are new drugs able to treat this common side effects on antipsychotics. These are the second generation VMAT2 inhibitors able to improve tardive dyskinesia without provoking significant side effects. So I think it’s important to know about this possibility but obviously the step number one to recognize this symptom which still is quite often not recognized by specialists and causes a lot of disability to people already being disabled because of psychosis and because of the need of a chronic treatment with antipsychotics.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
